The final draft guidance specifically applies to patients who have received at least three prior treatments, have progressed on their last treatment, and would otherwise be offered pomalidomide plus dexamethasone (pom-dex).
Approximately 5,900 people are diagnosed in the UK every year with multiple myeloma, an incurable blood cancer that affects a type of white blood cell called plasma cells.
The majority of patients will relapse and require subsequent therapy, with efficacy declining after each line of treatment…
